Correlation Between ProPhase Labs and Emergent Biosolutions

Can any of the company-specific risk be diversified away by investing in both ProPhase Labs and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ProPhase Labs and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ProPhase Labs and Emergent Biosolutions, you can compare the effects of market volatilities on ProPhase Labs and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ProPhase Labs with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of ProPhase Labs and Emergent Biosolutions.

Diversification Opportunities for ProPhase Labs and Emergent Biosolutions

-0.47

Correlation Coefficient

ProPhase Labs  Emergent Biosolutions

Very good diversification

The 3 months correlation between ProPhase and Emergent is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding ProPhase Labs and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and ProPhase Labs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ProPhase Labs are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of ProPhase Labs i.e., ProPhase Labs and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between ProPhase Labs and Emergent Biosolutions

Given the investment horizon of 90 days ProPhase Labs is expected to under-perform the Emergent Biosolutions. But the stock apears to be less risky and, when comparing its historical volatility, ProPhase Labs is 1.38 times less risky than Emergent Biosolutions. The stock trades about -0.2 of its potential returns per unit of risk. The Emergent Biosolutions is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  601.00  in Emergent Biosolutions on September 15, 2024 and sell it today you would earn a total of  268.00  from holding Emergent Biosolutions or generate 44.59% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

ProPhase Labs  vs.  Emergent Biosolutions

ProPhase Labs

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ProPhase Labs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Emergent Biosolutions

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with ProPhase Labs and Emergent Biosolutions

The main advantage of trading using opposite ProPhase Labs and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ProPhase Labs position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.

The idea behind ProPhase Labs and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.